This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere VT) | MicrobiomeTrials
← Back to trials NCT07585968
Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere VT) Recruiting NA INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-08-17Est. Completion: 2028-03
Enrollment target: 260 participantsLocations South Denver Cardiology Associates, Littleton, Colorado, United States Ascension Saint Vincent Hospital - Indianapolis, Indianapolis, Indiana, United States Northwell Health Lenox Hill Hospital, Manhasset, New York, United States NYU Langone Medical Center, New York, New York, United States Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States The Ohio State University Wexner Medical Center, Columbus, Ohio, United States Texas Cardiac Arrhythmia Research Foundation, Austin, Texas, United States Other microbiome trials you might be interested in Ventricular Arrhythmia
Background:
Ventricular arrhythmia is an abnormal pulse rhythm that starts in the lower part of the heart (ventricles).…
Atlanta, United States Completed Dec 1, 2026
Catecholaminergic Polymorphic Ventricular Tachycardia
This is a Phase 1b, Multicenter, Open-Label, Dose Finding Study to Investigate the Safety and Tolerability of a Single I…
Boston, United States Est. completion Jun 2027